<DOC>
	<DOCNO>NCT01066884</DOCNO>
	<brief_summary>This single arm study assess safety efficacy Tarceva monotherapy patient advance non-small cell lung cancer . Patients receive Tarceva 150mg p.o . daily . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study First Second Line Treatment With Tarceva ( Erlotinib ) Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient &gt; = 18 year age ; inoperable , locally advanced , recurrent metastatic ( Stage IIIB/IV ) nonsmall cell lung cancer ; ECOG performance status 03 ; previously untreated , fail one prior course standard systemic chemotherapy and/or radiotherapy . prior systemic antitumor therapy HER1/EGFR inhibitor ; unstable systemic disease ; malignancy within 5 year ( except adequately treated cancer situ cervix , basal squamous cell skin cancer ; significant ophthalmologic abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>